Skip to main content
Sun Pharma vs. Novo Nordisk: Semaglutide Litigation Update (Dec 2025)

The Battle for Semaglutide: Novo Nordisk vs. Sun Pharma

By Pharma Insights | Updated: December 9, 2025 | Reading Time: 3 Mins

The race to capture the lucrative market for Semaglutide generics has intensified in India. As of December 2025, the Delhi High Court is witnessing a flurry of legal activity involving Danish giant Novo Nordisk and Indian generic major Sun Pharmaceutical Industries.

🚨 Key Update (Dec 9, 2025): Novo Nordisk has filed a fresh plea seeking to restrain Sun Pharma from dealing in the Semaglutide compound.

1. The Core Dispute

At the heart of this litigation is Indian Patent No. 262697. Novo Nordisk, the innovator behind Ozempic and Wegovy, is seeking a permanent injunction to prevent Sun Pharma from manufacturing, selling, or exporting the active pharmaceutical ingredient (Semaglutide) before the patent's expiration.

2. The "Dr. Reddy's" Precedent

This lawsuit does not exist in a vacuum. It is being heard in the immediate shadow of a landmark ruling delivered on December 2, 2025, involving Dr. Reddy's Laboratories (DRL).

In that parallel case, the Delhi High Court delivered a split verdict that is likely to influence the Sun Pharma outcome:

  • Domestic Sales Blocked: DRL was restrained from selling Semaglutide within India until the patent expires.
  • Exports Allowed: Crucially, the court refused to stop DRL from manufacturing the drug for export to countries where the patent is no longer valid.

3. Legal Arguments & Strategies

Novo Nordisk's Stance

Novo argues that manufacturing the drug in India—even if solely for export—constitutes an infringement of their valid Indian patent rights. They are attempting to hold the line until the formulation patent expires in March 2026.

Sun Pharma's Defense

Sun Pharma, aligned with other generic manufacturers, relies on two main pillars:

  1. Patent Invalidity: Arguing that the core innovation patent expired in 2024 and the current patent represents "evergreening."
  2. Section 107A (Bolar Exemption): Utilizing Indian Patent Law which permits manufacturing for regulatory development and export to non-patent markets.

4. Strategic Implications for 2026

For investors and industry watchers, the implications are clear. The litigation is essentially a "holding action" by Novo Nordisk.

While Sun Pharma may be blocked from the Indian domestic market for a few more months, they are likely securing the right to manufacture and stockpile the drug immediately. This positions them for a rapid launch the moment the patent cliff arrives in March 2026.

Disclaimer: This article provides a summary of ongoing litigation for informational purposes only and does not constitute legal advice. Patent status and court rulings are subject to change.

Comments

Post a Comment

Popular posts from this blog

Transforming Healthcare: The Role of Artificial Intelligence in Pharmaceuticals and Medical Devices.

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...
Post a Comment
Read more

Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

The pharma monster has offered five of its ophthalmic medications to eye treatment organization Harrow for a one-time frame installment of $130 million, or more extra achievement installments of $45 million. The deal incorporates waterfall medical procedure recuperation eye drops Ilevro and Nevanac, bacterial conjunctivitis eyedrop Vigamox, irritation eye drops Maxidex and the injectable Triesence. The arrangement makes Harrow famous into "an administrative role in the U.S. ophthalmic drugs market," Imprint L. Baum, Harrow's Chief and executive, said in an assertion. "We know these items quite well and have long appreciated and respected them for the worth they have conveyed to great many U.S. eyecare experts and a huge number of their patients," Baum added. The arrangement will probably close during the main quarter of 2023. A while later, Novartis will in any case possess the items beyond the U.S. U.S. Novartis "stays focused on patients by supporting ad...
Post a Comment
Read more
Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Post a Comment
Read more